ReviewFrontiers in immunology2021
Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- The efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta‑analysis.Clinical and experimental medicine · 2023Pooled it
- The molecular mechanisms of platelets in tumor invasion and metastasis: a controversial role.Cancer biology & therapy · 2026Review
- Article
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- Platelet-derived mitochondrial transfer in cancer metastasis: mechanisms, functional consequences, and translational opportunities.Clinical & experimental metastasis · 2026Review
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Platelet-neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Dynamic systemic immune-inflammation index predicts survival after neoadjuvant immunotherapy in gastric cancer: A multicenter study.iScience · 2026Article
- Integrative analysis of tumor-educated platelets for stage-specific diagnosis, prognosis, and therapy in ovarian cancer.Discover oncology · 2026Article
- The Tumor-Platelet-Immune Interface: Driving Metastasis, Pre-Metastatic Niche Formation and Therapeutic Vulnerabilities.Expert reviews in molecular medicine · 2026Review
- Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis.Nature communications · 2026Article
- Thrombopoiesis meets tumorigenesis: unlocking the diagnostic and prognostic potential of platelet indices in breast cancer- a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Ononin suppresses tumor-induced platelet activation and invasion and enhances cell-cycle arrest and apoptosis in triple-negative breast cancer cells.Scientific reports · 2026Article
- Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation.Experimental hematology & oncology · 2026Review
- Interferon-α enhances NK cell function to counteract autologous platelet-mediated tumor immune evasion.Cancer cell international · 2026Article
- Dynamic Immune-Nutritional Indices as Powerful Predictors of Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.Journal of clinical medicine · 2026Article
- Association between platelet-to-lymphocyte ratio and high risk for prostate cancer among middle-aged and older US men.Scientific reports · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing insights in the complex interactions between metastatic cancer-cells and platelets have revealed that platelet tumor cell interactions in the blood stream are an important factor supporting tumor metastasis. An increased coagulability of platelets facilitates the vascular evasion and establishment of solid tumor metastasis. Furthermore, platelets can support an immunosuppressive tumor microenvironment or shield tumor cells directly from engagement of cytotoxic lymphocytes as e.g., natural killer (NK) cells. Platelets are both in the tumor microenvironment and systemically the quantitatively most important source of TGF-β, which is a key cytokine for immunosuppression in the tumor microenvironment. If similar platelet-tumor interactions are of physiological relevance in hematological malignancies remains less well-studied. This might be important, as T- and NK cell mediated graft vs. leukemia effects (GvL) are well-documented and malignant hematological cells have a high exposure to platelets compared to solid tumors. As NK cell-based immunotherapies gain increasing attention as a therapeutic option for patients suffering from hematological and other malignancies, we review the known interactions between platelets and NK cells in the solid tumor setting and discuss how these could also apply to hematological cancers. We furthermore explore the possible implications for NK cell therapy in patients with solid tumors and patients who depend on frequent platelet transfusions. As platelets have a protective and supportive effect on cancer cells, the impact of platelet transfusion on immunotherapy and the combination of immunotherapy with platelet inhibitors needs to be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.